Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for ...

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...

Duchenne muscular dystrophy patient died after being treated with the gene therapy delandistrogene moxeparvovec (Elevidys), ...

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene ...

在今日的市场动态中，生物技术公司Sarepta ...

Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...

基因治疗的潜力与风险并存。Sarepta作为一家致力于开发针对DMD的创新疗法的公司，其Elevidys的研发受到了广泛关注。DMD是一种严重的遗传性肌肉疾病，患者在儿童时期便开始出现肌肉萎缩，逐渐导致失去行走能力，最终可能危及生命。基因疗法的出现，为这些患者带来了新的希望，但同时也伴随着巨大的不确定性。

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio ...

A patient has died after receiving Sarepta Therapeutics’ approved gene therapy for Duchenne muscular dystrophy — the second fatality reported by the company in the past three months.

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a ...

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain ...